Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS.

Pharmacol Ther. 2012 Sep;135(3):327-36. doi: 10.1016/j.pharmthera.2012.06.005. Epub 2012 Jun 27. Review.

2.

Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.

Bochner BS.

Clin Exp Allergy. 2009 Mar;39(3):317-24. doi: 10.1111/j.1365-2222.2008.03173.x. Review.

4.

The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation.

Kiwamoto T, Katoh T, Tiemeyer M, Bochner BS.

Curr Opin Allergy Clin Immunol. 2013 Feb;13(1):106-11. doi: 10.1097/ACI.0b013e32835b594a. Review.

5.

Siglec-8 and Siglec-F, the new therapeutic targets in asthma.

Farid SSh, Mirshafiey A, Razavi A.

Immunopharmacol Immunotoxicol. 2012 Oct;34(5):721-6. doi: 10.3109/08923973.2011.589453. Epub 2012 Feb 11. Review.

PMID:
22324980
6.

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils.

Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jones C, Cromie KD, Crocker PR, Rothenberg ME, Bochner BS.

Allergy. 2008 Sep;63(9):1156-63. doi: 10.1111/j.1398-9995.2008.01709.x.

7.

Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement.

Yokoi H, Choi OH, Hubbard W, Lee HS, Canning BJ, Lee HH, Ryu SD, von Gunten S, Bickel CA, Hudson SA, Macglashan DW Jr, Bochner BS.

J Allergy Clin Immunol. 2008 Feb;121(2):499-505.e1. Epub 2007 Nov 26.

PMID:
18036650
8.

Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.

Kiwamoto T, Katoh T, Evans CM, Janssen WJ, Brummet ME, Hudson SA, Zhu Z, Tiemeyer M, Bochner BS.

J Allergy Clin Immunol. 2015 May;135(5):1329-40.e1-9. doi: 10.1016/j.jaci.2014.10.027. Epub 2014 Dec 12.

9.

Siglecs as targets for therapy in immune-cell-mediated disease.

O'Reilly MK, Paulson JC.

Trends Pharmacol Sci. 2009 May;30(5):240-8. doi: 10.1016/j.tips.2009.02.005. Epub 2009 Apr 7. Review.

10.

Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression.

Hudson SA, Herrmann H, Du J, Cox P, Haddad el-B, Butler B, Crocker PR, Ackerman SJ, Valent P, Bochner BS.

J Clin Immunol. 2011 Dec;31(6):1045-53. doi: 10.1007/s10875-011-9589-4. Epub 2011 Sep 22.

11.

Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils.

Zhang M, Angata T, Cho JY, Miller M, Broide DH, Varki A.

Blood. 2007 May 15;109(10):4280-7. Epub 2007 Feb 1.

12.

Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis x.

Hudson SA, Bovin NV, Schnaar RL, Crocker PR, Bochner BS.

J Pharmacol Exp Ther. 2009 Aug;330(2):608-12. doi: 10.1124/jpet.109.152439. Epub 2009 May 19.

13.

Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils.

Kikly KK, Bochner BS, Freeman SD, Tan KB, Gallagher KT, D'alessio KJ, Holmes SD, Abrahamson JA, Erickson-Miller CL, Murdock PR, Tachimoto H, Schleimer RP, White JR.

J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1093-100.

PMID:
10856141
14.

Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis.

Nutku E, Aizawa H, Hudson SA, Bochner BS.

Blood. 2003 Jun 15;101(12):5014-20. Epub 2003 Feb 27.

15.

Sialyltransferase ST3Gal-III regulates Siglec-F ligand formation and eosinophilic lung inflammation in mice.

Suzukawa M, Miller M, Rosenthal P, Cho JY, Doherty TA, Varki A, Broide D.

J Immunol. 2013 Jun 15;190(12):5939-48. doi: 10.4049/jimmunol.1203455. Epub 2013 May 15.

16.

Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling.

Song DJ, Cho JY, Lee SY, Miller M, Rosenthal P, Soroosh P, Croft M, Zhang M, Varki A, Broide DH.

J Immunol. 2009 Oct 15;183(8):5333-41. doi: 10.4049/jimmunol.0801421. Epub 2009 Sep 25.

17.

IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils.

Na HJ, Hudson SA, Bochner BS.

Cytokine. 2012 Jan;57(1):169-74. doi: 10.1016/j.cyto.2011.10.007. Epub 2011 Nov 12.

18.

Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.

Erickson-Miller CL, Freeman SD, Hopson CB, D'Alessio KJ, Fischer EI, Kikly KK, Abrahamson JA, Holmes SD, King AG.

Exp Hematol. 2003 May;31(5):382-8.

PMID:
12763136
19.

Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.

Schleimer RP, Schnaar RL, Bochner BS.

Curr Opin Allergy Clin Immunol. 2016 Feb;16(1):24-30. doi: 10.1097/ACI.0000000000000234. Review.

20.

Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis.

Rubinstein E, Cho JY, Rosenthal P, Chao J, Miller M, Pham A, Aceves SS, Varki A, Broide DH.

J Pediatr Gastroenterol Nutr. 2011 Oct;53(4):409-16. doi: 10.1097/MPG.0b013e3182182ff8.

Supplemental Content

Support Center